Caseware UK (AP4) 2024.0.164 2024.0.164 2025-03-312025-03-312024-04-0117false17falsefalsefalse 07196230 2024-04-01 2025-03-31 07196230 2023-04-01 2024-03-31 07196230 2025-03-31 07196230 2024-03-31 07196230 c:Director1 2024-04-01 2025-03-31 07196230 c:Director2 2024-04-01 2025-03-31 07196230 c:Director3 2024-04-01 2025-03-31 07196230 c:Director4 2024-04-01 2025-03-31 07196230 c:Director5 2024-04-01 2025-03-31 07196230 c:Director6 2024-04-01 2025-03-31 07196230 c:RegisteredOffice 2024-04-01 2025-03-31 07196230 d:Buildings d:LongLeaseholdAssets 2024-04-01 2025-03-31 07196230 d:Buildings d:LongLeaseholdAssets 2025-03-31 07196230 d:Buildings d:LongLeaseholdAssets 2024-03-31 07196230 d:PlantMachinery 2024-04-01 2025-03-31 07196230 d:PlantMachinery 2025-03-31 07196230 d:PlantMachinery 2024-03-31 07196230 d:PlantMachinery d:OwnedOrFreeholdAssets 2024-04-01 2025-03-31 07196230 d:FurnitureFittings 2024-04-01 2025-03-31 07196230 d:FurnitureFittings 2025-03-31 07196230 d:FurnitureFittings 2024-03-31 07196230 d:FurnitureFittings d:OwnedOrFreeholdAssets 2024-04-01 2025-03-31 07196230 d:ComputerEquipment 2024-04-01 2025-03-31 07196230 d:ComputerEquipment 2025-03-31 07196230 d:ComputerEquipment 2024-03-31 07196230 d:ComputerEquipment d:OwnedOrFreeholdAssets 2024-04-01 2025-03-31 07196230 d:OtherPropertyPlantEquipment 2024-04-01 2025-03-31 07196230 d:OtherPropertyPlantEquipment 2025-03-31 07196230 d:OtherPropertyPlantEquipment 2024-03-31 07196230 d:OtherPropertyPlantEquipment d:OwnedOrFreeholdAssets 2024-04-01 2025-03-31 07196230 d:OwnedOrFreeholdAssets 2024-04-01 2025-03-31 07196230 d:PatentsTrademarksLicencesConcessionsSimilar 2024-04-01 2025-03-31 07196230 d:Goodwill 2025-03-31 07196230 d:Goodwill 2024-03-31 07196230 d:CurrentFinancialInstruments 2025-03-31 07196230 d:CurrentFinancialInstruments 2024-03-31 07196230 d:Non-currentFinancialInstruments 2025-03-31 07196230 d:Non-currentFinancialInstruments 2024-03-31 07196230 d:CurrentFinancialInstruments d:WithinOneYear 2025-03-31 07196230 d:CurrentFinancialInstruments d:WithinOneYear 2024-03-31 07196230 d:Non-currentFinancialInstruments d:AfterOneYear 2025-03-31 07196230 d:Non-currentFinancialInstruments d:AfterOneYear 2024-03-31 07196230 d:RetainedEarningsAccumulatedLosses 2025-03-31 07196230 d:RetainedEarningsAccumulatedLosses 2024-03-31 07196230 d:AcceleratedTaxDepreciationDeferredTax 2025-03-31 07196230 d:AcceleratedTaxDepreciationDeferredTax 2024-03-31 07196230 c:FRS102 2024-04-01 2025-03-31 07196230 c:Audited 2024-04-01 2025-03-31 07196230 c:FullAccounts 2024-04-01 2025-03-31 07196230 c:CompanyLimitedByGuarantee 2024-04-01 2025-03-31 07196230 d:WithinOneYear 2025-03-31 07196230 d:WithinOneYear 2024-03-31 07196230 d:BetweenOneFiveYears 2025-03-31 07196230 d:BetweenOneFiveYears 2024-03-31 07196230 2 2024-04-01 2025-03-31 07196230 e:PoundSterling 2024-04-01 2025-03-31 iso4217:GBP xbrli:pure
Company registration number: 07196230







DIRECTORS' REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED
31 MARCH 2025


STEVENAGE BIOSCIENCE CATALYST
(A Company Limited by Guarantee)






































img540f.png                        

 


STEVENAGE BIOSCIENCE CATALYST
 
(A Company Limited by Guarantee)
 


 
COMPANY INFORMATION


Directors
L Drummond 
S A Forsyth 
J A Green 
A J Hunter 
UP Phadke 
G P Rivers 




Registered number
07196230



Registered office
Stevenage Bioscience Catalyst
Gunnels Wood Road

Stevenage

Hertfordshire

SG1 2FX




Independent auditors
Menzies LLP
Chartered Accountants & Statutory Auditor

Richmond House

Walkern Road

Stevenage

Herts

SG1 3QP





 


STEVENAGE BIOSCIENCE CATALYST
 
(A Company Limited by Guarantee)
 



CONTENTS



Page
Directors' Report
1 - 2
Independent Auditors' Report
3 - 6
Statement of Comprehensive Income
7
Statement of Comprehensive Income
Statement of Financial Position
8 - 9
Notes to the Financial Statements
10 - 19


 


STEVENAGE BIOSCIENCE CATALYST
 
(A Company Limited by Guarantee)
 


 
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 MARCH 2025

The directors present their report and the financial statements for the year ended 31 March 2025.

Directors' responsibilities statement

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable law and regulations.
 
Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland'. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period.

 In preparing these financial statements, the directors are required to:


select suitable accounting policies for the Company's financial statements and then apply them consistently;

make judgments and accounting estimates that are reasonable and prudent;

prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and to enable them to ensure that the financial statements comply with the Companies Act 2006They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Principal activity

The principal activity of the company is the management and development of an independent bioscience park.

Directors

The directors who served during the year were:

L Drummond 
S A Forsyth 
J A Green 
A J Hunter 
UP Phadke 
G P Rivers 

Disclosure of information to auditors

Each of the persons who are directors at the time when this Directors' Report is approved has confirmed that:
 
so far as the director is aware, there is no relevant audit information of which the Company's auditors are unaware, and

the director has taken all the steps that ought to have been taken as a director in order to be aware of any relevant audit information and to establish that the Company's auditors are aware of that information.

Auditors

The auditorsMenzies LLPwill be proposed for reappointment in accordance with section 485 of the Companies Act 2006.

Page 1

 


STEVENAGE BIOSCIENCE CATALYST

(A Company Limited by Guarantee)
 


 
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025

Small companies note

In preparing this report, the directors have taken advantage of the small companies exemptions provided by section 415A of the Companies Act 2006.

This report was approved by the board and signed on its behalf.
 





................................................
A J Hunter
Director

Date: 16 December 2025

Page 2

 


STEVENAGE BIOSCIENCE CATALYST
 
(A Company Limited by Guarantee)
 

img0e65.png
 
INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF STEVENAGE BIOSCIENCE CATALYST

Opinion


We have audited the financial statements of Stevenage Bioscience Catalyst (the 'Company') for the year ended 31 March 2025, which comprise the Statement of Comprehensive Income, the Statement of Comprehensive Income, the Statement of Financial Position and the related notes, including a summary of significant accounting policiesThe financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).


In our opinion the financial statements:


give a true and fair view of the state of the Company's affairs as at 31 March 2025 and of its loss for the year then ended;
have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
have been prepared in accordance with the requirements of the Companies Act 2006.


Basis for opinion


We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.


Conclusions relating to going concern


In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.


Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.


Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.


Other information


The other information comprises the information included in the Annual Report other than the financial statements and our Auditors' Report thereon. The directors are responsible for the other information contained within the Annual ReportOur opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.


We have nothing to report in this regard.


Page 3

 


STEVENAGE BIOSCIENCE CATALYST

(A Company Limited by Guarantee)


img6f61.png
 
INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF STEVENAGE BIOSCIENCE CATALYST (CONTINUED)

Opinion on other matters prescribed by the Companies Act 2006
 

In our opinion, based on the work undertaken in the course of the audit:


the information given in the Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
the Directors' Report has been prepared in accordance with applicable legal requirements.


Matters on which we are required to report by exception
 

In the light of the knowledge and understanding of the Company and its environment obtained in the course of the audit, we have not identified material misstatements in the Directors' Report.


We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:


adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
the financial statements are not in agreement with the accounting records and returns; or
certain disclosures of directors' remuneration specified by law are not made; or
we have not received all the information and explanations we require for our audit; or
the directors were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemptions in preparing the Directors' Report and from the requirement to prepare a Strategic Report.


Responsibilities of directors
 

As explained more fully in the Directors' Responsibilities Statement set out on page 1, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.


In preparing the financial statements, the directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.


Page 4

 


STEVENAGE BIOSCIENCE CATALYST

(A Company Limited by Guarantee)


img19a5.png
 
INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF STEVENAGE BIOSCIENCE CATALYST (CONTINUED)

Auditors' responsibilities for the audit of the financial statements
 

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors' Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.


Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:
•The Company is subject to laws and regulations that directly affect the financial statements including financial reporting legislation. We determined that the following laws and regulations were most significant including UK Companies Act, employment law, health and safety, pensions legislation and tax legislation.
 
•We understood how the Company is complying with those legal and regulatory frameworks by making inquiries to management and those responsible for legal and compliance procedures. We assessed the extent of compliance with these legal and compliance procedures as part of our procedures on the related financial statement items.
 
•The engagement partner assessed whether the engagement team collectively had the appropriate competence and capabilities to identify or recognize non-compliance with laws and regulations. The assessment did not identify any issues in this area.
 
•We assessed the susceptibility of the Company’s financial statements to material misstatement, including how fraud might occur. We identified the risk of override of controls as the area where the financial statements were most susceptible to material misstatement due to fraud. Audit procedures performed by the engagement team included:
 
•Identifying and assessing the design effectiveness of controls management has in place to prevent and detect fraud;
•Understanding how those charged with governance considered and addressed the potential for override of controls or other inappropriate influence over the financial reporting process;
•Challenging assumptions and judgments made by management in its significant accounting estimates; and
•Identifying and testing journal entries, in particular any journal entries posted with unusual account combinations.
 
The assessment did not identify any issues in these areas.
 
Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-complance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.


A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our Auditors' Report.


Page 5

 


STEVENAGE BIOSCIENCE CATALYST

(A Company Limited by Guarantee)


img7ba3.png
 
INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF STEVENAGE BIOSCIENCE CATALYST (CONTINUED)

Use of our report
 

This report is made solely to the Company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state to them in an Auditors' Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members, as a body, for our audit work, for this report, or for the opinions we have formed.





James Fox FCCA ACA (Senior Statutory Auditor)
  
for and on behalf of
Menzies LLP
 
Chartered Accountants
Statutory Auditor
  
Richmond House
Walkern Road
Stevenage
Herts
SG1 3QP

17 December 2025
Page 6

 


STEVENAGE BIOSCIENCE CATALYST
 
(A Company Limited by Guarantee)
 


 
STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 MARCH 2025

2025
2024
Note
£
£

  

Turnover
  
4,091,025
5,458,653

Gross profit
  
4,091,025
5,458,653

Administrative expenses
  
(6,197,041)
(6,256,069)

Other operating income
  
1,119,675
1,410,318

Operating (loss)/profit
  
(986,341)
612,902

Interest receivable and similar income
  
101,968
121,431

(Loss)/profit before tax
  
(884,373)
734,333

Tax on (loss)/profit
  
201,195
(120,441)

(Loss)/profit for the financial year
  
(683,178)
613,892

There was no other comprehensive income for 2025 (2024:£NIL).

The notes on pages 10 to 19 form part of these financial statements.

Page 7

 


STEVENAGE BIOSCIENCE CATALYST
  
(A Company Limited by Guarantee)
REGISTERED NUMBER:07196230



STATEMENT OF FINANCIAL POSITION
AS AT 31 MARCH 2025

2025
2024
Note
£
£

Fixed assets
  

Tangible assets
 8 
18,398,860
18,490,989

  
18,398,860
18,490,989

Current assets
  

Debtors: amounts falling due within one year
 9 
2,050,925
3,536,344

Bank and cash balances
  
1,544,048
2,109,056

  
3,594,973
5,645,400

Creditors: amounts falling due within one year
 10 
(3,402,997)
(3,718,661)

Net current assets
  
 
 
191,976
 
 
1,926,739

Total assets less current liabilities
  
18,590,836
20,417,728

Creditors: amounts falling due after more than one year
 11 
(14,071,220)
(15,181,248)

Provisions for liabilities
  

Deferred tax
 12 
(216,923)
(250,609)

  
 
 
(216,923)
 
 
(250,609)

Net assets
  
4,302,693
4,985,871


Capital and reserves
  

Profit and loss account
  
4,302,693
4,985,871

  
4,302,693
4,985,871


Page 8

 


STEVENAGE BIOSCIENCE CATALYST
  
(A Company Limited by Guarantee)
REGISTERED NUMBER:07196230


    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 MARCH 2025

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




................................................
A J Hunter
Director

Date: 16 December 2025

The notes on pages 10 to 19 form part of these financial statements.

Page 9

 


STEVENAGE BIOSCIENCE CATALYST
 
(A Company Limited by Guarantee)
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

1.


General information

Stevenage Bioscience Catalyst ('the company') is a private company limited by guarantee incorporated in England and Wales. Registered number 07196230. The registered office and principal place of business is Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2FX.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies (see note 3).

The following principal accounting policies have been applied:

 
2.2

Going concern

The directors believe that the company is well placed to manage its business risks successfully and they have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. The company has net assets at the year end, of over £4.3m (2024: £4.9m), and the directors have performed a forward-looking review and are satisfied with the actions taken to support company operations for the foreseeable future. The director's use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

  
2.3

Revenue

Revenue represents rental income and amounts receivable for services provided to customers net of VAT and trade discounts. Amounts receivable for services are recognised on an accruals basis when they have been rendered. Rental income is accounted for on a straight-line basis over the term of lease to account for rent free periods.

 
2.4

Interest income

Interest income is recognised in profit or loss using the effective interest method.

 
2.5

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

Page 10

 


STEVENAGE BIOSCIENCE CATALYST
 
(A Company Limited by Guarantee)
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

2.Accounting policies (continued)

 
2.6

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Statement of Financial Position. The assets of the plan are held separately from the Company in independently administered funds.

 
2.7

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the reporting date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.


 
2.8

Intangible assets

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

 Amortisation is provided on the following bases:

Software
-
4 years straight line

Page 11

 


STEVENAGE BIOSCIENCE CATALYST
 
(A Company Limited by Guarantee)
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

2.Accounting policies (continued)

 
2.9

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Long-term leasehold property
-
4-40 years
Plant and machinery
-
2-15 years straight line
Fixtures and fittings
-
5-10 years straight line
Computer equipment
-
4 years straight line
Assets under construction
-
Not currently depreciated, until the asset is completed and in place to be used

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

  
2.10

Leases

Rentals payable under operating leases are charge to income on a straight-line basis over the term of the relevant lease.

  
2.11

Grants

Grants are credited to deferred income when they become receivable and then recognised in income in accordance with the accruals model of FRS 102. Grants towards capital expenditure are released to income over the expected useful life of the assets. Grants towards revenue expenditure are released to income as the related expenditure is incurred.

 
2.12

Financial Instruments

Financial instruments are recognised in the Company's Statement of financial position when the Company becomes party to the contractual provisions of the instrument.

Page 12

 


STEVENAGE BIOSCIENCE CATALYST
 
(A Company Limited by Guarantee)
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

3.


Judgments in applying accounting policies and key sources of estimation uncertainty

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.
Critical accounting estimates and assumptions
The Directors do not consider there to be any critical accounting estimates or assumptions in the financial statements.
Critical areas of judgement
A critical area of judgement has been applied in respect of the FRS 102 accounting requirement to recognise revenue where there is an exchange of services, Section 23 of FRS 102 'Revenue' requires revenue to be recognised when goods or services are exchanged which are dissimilar in a transaction that has commercial substance. The revenue recognised is measured at the fair value of the goods or services received if the fair value can be measured reliably.
The Directors have applied their judgement in determining that the buildings owned by Stevenage Bioscience Catalyst be treated as tangible fixed assets rather than as investment property. The basis for this reasoning being that while these buildings earn rentals they are also used in the supply of serviced lab and office space and creating a collaborative environment to support small businesses. Furthermore, Stevenage Bioscience Catalyst is itself a not-for-profit entity, therefore the buildings are not held for capital appreciation or as a long-term income stream.
Stevenage Bioscience Catalyst (SBC) has an arrangement with another party whereby SBC has provided laboratory space, landlord services and access to meeting rooms to the other party in return for the other party fitting out the laboratory with its own equipment and allowing SBC to use the fitted-out laboratory when the other party are not using it as a 'show lab' for its customers.
The Directors have applied their judgement in determining that revenue should not be recognised, for this exchange of dissimilar services, on the grounds that the transaction lacks commercial substance. This assessment is based on the Directors judgement that the service provided by the other party has not been exploited for further economic benefit by SBC, leading to increased profits or cash flows (that would not otherwise have been generated). In particular, the Directors have determined that SBC's rental income and facility charges to other tenants and its tenant occupancy levels have not increased as a result of the arrangement. This arrangement is considered by the Directors to be a long term arrangement for the benefit of the smaller entities within the eco-system. For VAT purposes the value of the services exchanged has been measured at £920,000 (2024: £380,000).


4.


Auditors' remuneration

During the year, the Company obtained the following services from the Company's auditors:


2025
2024
£
£

Fees payable to the Company's auditors for the audit of the Company's financial statements
24,250
20,000

5.


Employees

The average monthly number of employees, including directors, during the year was 17 (2024 - 17).

Page 13

 


STEVENAGE BIOSCIENCE CATALYST
 
(A Company Limited by Guarantee)
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

6.


Directors' remuneration

2025
2024
£
£

Directors' emoluments
390,472
372,747

Company contributions to defined contribution pension schemes
19,652
44,783

410,124
417,530


The highest paid director received remuneration of £307,020 (2024 - £269,962).

Page 14

 


STEVENAGE BIOSCIENCE CATALYST
 
(A Company Limited by Guarantee)
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

7.


Intangible assets




Software

£



Cost


At 1 April 2024
25,275



At 31 March 2025

25,275



Amortisation


At 1 April 2024
25,275



At 31 March 2025

25,275



Net book value



At 31 March 2025
-



At 31 March 2024
-




8.


Tangible fixed assets





Long-term leasehold property
Plant and machinery
Fixtures and fittings
Computer equipment
Assets under construction

£
£
£
£
£



Cost or valuation


At 1 April 2024
21,517,491
11,609,127
561,543
665,011
404,887


Additions
-
75,437
10,028
5,243
1,237,734


Disposals
-
(2,000)
-
-
-



At 31 March 2025

21,517,491
11,682,564
571,571
670,254
1,642,621



Depreciation


At 1 April 2024
7,316,297
7,755,152
378,488
571,796
245,337


Charge for the year on owned assets
511,119
838,259
36,198
34,995
-


Disposals
-
(2,000)
-
-
-



At 31 March 2025

7,827,416
8,591,411
414,686
606,791
245,337



Net book value
Page 15

 


STEVENAGE BIOSCIENCE CATALYST
 
(A Company Limited by Guarantee)
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

           8.Tangible fixed assets (continued)




At 31 March 2025
13,690,075
3,091,153
156,885
63,463
1,397,284



At 31 March 2024
14,201,194
3,853,975
183,055
93,215
159,550

Total

£



Cost or valuation


At 1 April 2024
34,758,059


Additions
1,328,442


Disposals
(2,000)



At 31 March 2025

36,084,501



Depreciation


At 1 April 2024
16,267,070


Charge for the year on owned assets
1,420,571


Disposals
(2,000)



At 31 March 2025

17,685,641



Net book value



At 31 March 2025
18,398,860



At 31 March 2024
18,490,989


9.


Debtors

2025
2024
£
£


Trade debtors
460,739
1,357,231

Other debtors
111,921
1,280,416

Prepayments and accrued income
1,311,000
898,697

Tax recoverable
167,265
-

2,050,925
3,536,344


Page 16

 


STEVENAGE BIOSCIENCE CATALYST
 
(A Company Limited by Guarantee)
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

10.


Creditors: Amounts falling due within one year

2025
2024
£
£

Trade creditors
845,258
954,864

Corporation tax
-
167,231

Other taxation and social security
73,817
168,259

Obligations under finance lease and hire purchase contracts
32,592
-

Other creditors
76,664
5,921

Accruals and deferred income
2,374,666
2,422,386

3,402,997
3,718,661



11.


Creditors: Amounts falling due after more than one year

2025
2024
£
£

Accruals and deferred income
14,071,220
15,181,248

14,071,220
15,181,248



12.


Deferred taxation




2025


£






At beginning of year
(250,609)


Charged to profit or loss
33,686



At end of year
(216,923)

The provision for deferred taxation is made up as follows:

2025
2024
£
£


Accelerated capital allowances
(216,923)
(250,609)

(216,923)
(250,609)

Page 17

 


STEVENAGE BIOSCIENCE CATALYST
 
(A Company Limited by Guarantee)
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025


13.


Company status

The company is a private company limited by guarantee and consequently does not have share capital. Each of the members is liable to contribute an amount not exceeding £1 towards the assets of the company in the event of liquidation. At 31 March 2025 there were 2 members (2024: 2).
As the company is limited by guarantee and by nature of voting rights there is no ultimate beneficial owner.


14.


Capital commitments


At 31 March 2025 the Company had capital commitments as follows:

2025
2024
£
£


Contracted for but not provided in these financial statements
16,174
19,861

16,174
19,861


15.


Commitments under operating leases

At 31 March 2025 the Company had future minimum lease payments due under non-cancellable operating leases for each of the following periods:

2025
2024
£
£


Not later than 1 year
37,902
31,222

Later than 1 year and not later than 5 years
6,249
20,573

44,151
51,795

Page 18

 


STEVENAGE BIOSCIENCE CATALYST
 
(A Company Limited by Guarantee)
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

16.


Related party transactions

Glaxosmithkline Limited is one of the members of Stevenage Bioscience Catalyst. It shares equal and joint control over the company with The Wellcome Trust.
During the year Stevenage Bioscience Catalyst made sales to Glaxosmithkline Limited totalling £nil (2024: £300).
During the year, the company recognised grants from its members as follows:
At the reporting date there are £2,905,994 (2024: £3,120,204) of grants received from Glaxosmithkline Limited included in deferred income which represent amounts spent on fixed assets. £214,210 (2024: £269,814) of deferred capital grant was released to income in the year in line with the depreciation charged on grant funded fixed assets and the disposal of grant funded assets. 
The Wellcome Trust is one of the members of Stevenage Bioscience Catalyst. It shares equal and joint control over the company with Glaxosmithkline Limited.
At the reporting date there are grants received from The Wellcome Trust of £1,830,508 (2024: £1,965,441) included in deferred income which represent amounts spent on fixed assets. £134,932 (2024: £169,958) of deferred capital grant has been released to profit and loss in the year in line with the depreciation and the disposal of grant funded assets. 
The Hertfordshire Local Enterprise Partnership Limited ceased to share a director in common with Stevenage Bioscience Catalyst during the year.
At the reporting date there are £779,705 (2024: £837,179) of grants received from Hertfordshire Local Enterprise Partnership Limited, included in deferred income which represent amounts spent on fixed assets. £57,474 (2024: £72,394) of deferred capital grant was released to income in the year in line with the depreciation charged on grant funded fixed assets and the disposal of grant funded assets.
During the year The Hertfordshire Local Enterprise Partnership Limited made purchases totalling £280  (2024: £nil) from Stevenage Bioscience Catalyst.
OI Pharma Partners Limited shares a director in common with Stevenage Bioscience Catalyst.
During the year OI Pharma Partners Limited made purchases totalling £1,790 (2024: £nil) from Stevenage Bioscience Catalyst.
Centre for Commercialisation Limited shares a director in common with Stevenage Bioscience Catalyst.
During the year Centre for Commercialisation Limited made purchases totalling £6,549 (2024: £nil) from Stevenage Bioscience Catalyst.
The Triple Chasm Company Limited shares a director in common with Stevenage Bioscience Catalyst.
During the year The Triple Chasm Company Limited made sales totalling £20,000 (2024: £15,044) to Stevenage Bioscience Catalyst.
Cartezia Cambridge Limited shares a director in common with Stevenage Bioscience Catalyst.
During the year Cartezia Cambridge Limited made sales totalling £nil (2024: £10,000) to Stevenage Bioscience Catalyst.
One Nucleus Limited shares a director in common with Stevenage Bioscience Catalyst.
During the year One Nucleus Limited made sales totalling £2,675 (2024: £2,290) to Stevenage Bioscience Catalyst.

 
Page 19